[20] ICH, “International conference on harmonisation of technical requirements for re-

gistration of pharmaceuticals for human use viral safety evaluation of biotechnology

products derived from cell lines of human or animal origin Q5A(R1),” 1999. https://

database.ich.org/sites/default/files/Q5A%28R1%29%20Guideline_0.pdf (accessed

Oct-2021).

[21] ICH, “International conference on harmonisation of technical requirements for re-

gistration of pharmaceuticals for human use ich harmonised tripartite guideline de-

rivation and characterisation of cell substrates used for production of biotechnological/

biological,” 1997. https://database.ich.org/sites/default/files/Q5D%20Guideline.pdf

(accessed Oct-2021).

[22] FDA (U. S. Food and Drug Administration) “Guidance for Industry: Characterization

and qualification of cell substrates and other biological materials used in the pro-

duction of viral vaccines for infectious disease indications,” 2010. https://www.

fda.gov/regulatory-information/search-fda-guidance-documents/characterization-

and-qualification-cell-substrates-and-other-biological-materials-used-production (ac-

cessed Oct-2021).

[23] U. S. Pharmacopeia, “General Chapters: <1050> VIRAL SAFETY EVALUATION

OF BIOTECHNOLOGY PRODUCTS DERIVED FROM CELL LINES OF

HUMAN OR ANIMAL ORIGIN,” 2011. http://www.pharmacopeia.cn/v29240/

usp29nf24s0_c1050_viewall.html (accessed Oct‐2021).

[24] EMA, “Guideline on virus safety evaluation of biotechnological investigational med-

icinal products (EMEA/CHMP/BWP/398498/2005),” 2008. https://www.ema.

europa.eu/en/documents/scientific-guideline/guideline-virus-safety-evaluation-

biotechnological-investigational-medicinal-products_en.pdf (accessed Oct-2021).

[25] EMA, “Guideline on the use of porcine trypsin used in the manufacture of human

biological medicinal products (EMA/CHMP/BWP/814397/2011),” 2014. https://

www.ema.europa.eu/en/documents/scientific-guideline/guideline-use-porcine-

trypsin-used-manufacture-human-biological-medicinal-products_en.pdf (accessed

Oct-2021).

[26] EMA, “Guideline on the use of bovine serum in the manufacture of human biological

medicinal products (CPMP/BWP/1793/02),” 2013. https://www.ema.europa.eu/en/

documents/scientific-guideline/guideline-use-bovine-serum-manufacture-human-

biological-medicinal-products_en.pdf (accessed Oct-2021).

[27] M. McLeish, A. Fraile, and F. García-Arenal, “Ecological complexity in plant virus

host range evolution,” Adv. Virus Res., vol. 101, pp. 293–339, Jan. 2018.

[28] J. Gombold et al., “Systematic evaluation of in vitro and in vivo adventitious virus

assays for the detection of viral contamination of cell banks and biological pro-

ducts,” Vaccine, vol. 32, no. 24, pp. 2916–2926, May 2014.

[29] C. Lambert et al., “Considerations for optimization of high-throughput sequencing

bioinformatics pipelines for virus detection,” Viruses, vol. 10, no. 10, 1–28, Oct. 2018.

[30] B. Metz, C. Hendriksen, W. Jiskoot, and G. Kersten, “Reduction of animal use in

human vaccine quality control: opportunities and problems,” Vaccine, vol. 20,

no. 19–20, pp. 2411–2430, Jun. 2002.

[31] G. Kärber, “Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche,”

Naunyn-Schmiedebergs Arch. für Exp. Pathol. und Pharmakologie 1931 1624,

vol. 162, no. 4, pp. 480–483, Jul. 1931.

[32] L. J. Reed and H. Muench, “A simple method of estimating fifty per cent end-

points,” Am. J. Epidemiol., vol. 27, no. 3, pp. 493–497, May 1938.

[33] C. Spearman, “The method of ‘Right and wrong cases’ (‘Constant stimuli’) without

Gauss’s Formulae,” Br. J. Psychol. 1904–1920, vol. 2, no. 3, pp. 227–242, 1908.

Cell lines for vaccine production

77